• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

33 种癌症类型中肿瘤抑制基因失活事件的特征。

Characterization of Tumor-Suppressor Gene Inactivation Events in 33 Cancer Types.

机构信息

Center for Precision Health, School of Biomedical Informatics, The University of Texas Health Science Center at Houston, Houston, TX 77030, USA.

Center for Precision Health, School of Biomedical Informatics, The University of Texas Health Science Center at Houston, Houston, TX 77030, USA; MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences, Houston, TX 77030, USA; Human Genetics Center, School of Public Health, The University of Texas Health Science Center at Houston, Houston, TX 77030, USA.

出版信息

Cell Rep. 2019 Jan 8;26(2):496-506.e3. doi: 10.1016/j.celrep.2018.12.066.

DOI:10.1016/j.celrep.2018.12.066
PMID:30625331
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7375892/
Abstract

We systematically investigated the landscape of tumor-suppressor gene (TSG) inactivation events in 33 cancer types by quantitatively measuring their global and local genomic features and their transcriptional and signaling footprints. Using The Cancer Genome Atlas data, we identified with high confidence 337 TSG × cancer events in 30 cancer types, of which 277 were unique events. The majority (91.0%) of these events had a significant downstream impact measured by reduced expression of the TSG itself (cis-effect), disturbance of the transcriptome (trans-effect), or combinatorial effects. Importantly, the transcriptomic changes associated with TSG inactivation events were stronger than the cancer lineage difference, and the same TSGs inactivated in different cancer types tended to cluster together. Several TSGs (e.g., RB1, TP53, and CDKN2A) involved in the regulation of the cell-cycle-formed clusters. Finally, we constructed subnetworks of the TSG × cancer inactivation events, including the local genes frequently disturbed upon the inactivation events.

摘要

我们通过定量测量 33 种癌症类型的全局和局部基因组特征及其转录和信号足迹,系统地研究了肿瘤抑制基因 (TSG) 失活事件的全景。使用癌症基因组图谱数据,我们在 30 种癌症类型中确定了 337 个 TSG×癌症事件,其中 277 个是独特事件。这些事件中的大多数(91.0%)通过 TSG 自身表达降低(顺式效应)、转录组紊乱(反式效应)或组合效应来衡量,都具有显著的下游影响。重要的是,与 TSG 失活事件相关的转录组变化强于癌症谱系差异,并且在不同癌症类型中失活的相同 TSG 往往聚集在一起。一些 TSG(如 RB1、TP53 和 CDKN2A)参与细胞周期的调节,形成了聚类。最后,我们构建了 TSG×癌症失活事件的子网,包括失活事件后经常受到干扰的局部基因。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8c7d/7375892/bbced6f9666c/nihms-1611750-f0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8c7d/7375892/63cade1cc8c7/nihms-1611750-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8c7d/7375892/88d18246fd2a/nihms-1611750-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8c7d/7375892/6e908d7c0d94/nihms-1611750-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8c7d/7375892/a1225caa8a1d/nihms-1611750-f0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8c7d/7375892/d1b98f002304/nihms-1611750-f0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8c7d/7375892/bbced6f9666c/nihms-1611750-f0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8c7d/7375892/63cade1cc8c7/nihms-1611750-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8c7d/7375892/88d18246fd2a/nihms-1611750-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8c7d/7375892/6e908d7c0d94/nihms-1611750-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8c7d/7375892/a1225caa8a1d/nihms-1611750-f0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8c7d/7375892/d1b98f002304/nihms-1611750-f0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8c7d/7375892/bbced6f9666c/nihms-1611750-f0006.jpg

相似文献

1
Characterization of Tumor-Suppressor Gene Inactivation Events in 33 Cancer Types.33 种癌症类型中肿瘤抑制基因失活事件的特征。
Cell Rep. 2019 Jan 8;26(2):496-506.e3. doi: 10.1016/j.celrep.2018.12.066.
2
Loss of Tumor Suppressor Gene Function in Human Cancer: An Overview.人类癌症中肿瘤抑制基因功能的丧失:概述
Cell Physiol Biochem. 2018;51(6):2647-2693. doi: 10.1159/000495956. Epub 2018 Dec 12.
3
Compound Genomic Alterations of TP53, PTEN, and RB1 Tumor Suppressors in Localized and Metastatic Prostate Cancer.局部和转移性前列腺癌中 TP53、PTEN 和 RB1 肿瘤抑制因子的复合基因组改变。
Eur Urol. 2019 Jul;76(1):89-97. doi: 10.1016/j.eururo.2018.11.045. Epub 2018 Dec 12.
4
Epigenetic inactivation of the RASSF1A 3p21.3 tumor suppressor gene in both clear cell and papillary renal cell carcinoma.在透明细胞和乳头状肾细胞癌中,RASSF1A 3p21.3肿瘤抑制基因的表观遗传失活。
Cancer Res. 2001 Oct 1;61(19):7277-81.
5
Combinatorial CRISPR/Cas9 Screening Reveals Epistatic Networks of Interacting Tumor Suppressor Genes and Therapeutic Targets in Human Breast Cancer.组合型 CRISPR/Cas9 筛选揭示了人类乳腺癌中相互作用的肿瘤抑制基因和治疗靶点的上位网络。
Cancer Res. 2021 Dec 15;81(24):6090-6105. doi: 10.1158/0008-5472.CAN-21-2555. Epub 2021 Sep 24.
6
Evolutionary dynamics of tumor suppressor gene inactivation.肿瘤抑制基因失活的进化动力学
Proc Natl Acad Sci U S A. 2004 Jul 20;101(29):10635-8. doi: 10.1073/pnas.0400747101. Epub 2004 Jul 13.
7
Concordance of copy number loss and down-regulation of tumor suppressor genes: a pan-cancer study.拷贝数缺失与肿瘤抑制基因下调的一致性:一项泛癌研究。
BMC Genomics. 2016 Aug 22;17 Suppl 7(Suppl 7):532. doi: 10.1186/s12864-016-2904-y.
8
Oncogenes and tumor suppressor genes: comparative genomics and network perspectives.癌基因与肿瘤抑制基因:比较基因组学与网络视角
BMC Genomics. 2015;16 Suppl 7(Suppl 7):S8. doi: 10.1186/1471-2164-16-S7-S8. Epub 2015 Jun 11.
9
Inactivation of the von Hippel-Lindau (VHL) tumour suppressor gene and allelic losses at chromosome arm 3p in primary renal cell carcinoma: evidence for a VHL-independent pathway in clear cell renal tumourigenesis.原发性肾细胞癌中冯·希佩尔-林道(VHL)肿瘤抑制基因的失活及3号染色体短臂的等位基因缺失:透明细胞肾肿瘤发生中存在不依赖VHL途径的证据
Genes Chromosomes Cancer. 1998 Jul;22(3):200-9. doi: 10.1002/(sici)1098-2264(199807)22:3<200::aid-gcc5>3.0.co;2-#.
10
Distinct and competitive regulatory patterns of tumor suppressor genes and oncogenes in ovarian cancer.卵巢癌中肿瘤抑制基因和癌基因的独特且竞争性的调控模式。
PLoS One. 2012;7(8):e44175. doi: 10.1371/journal.pone.0044175. Epub 2012 Aug 30.

引用本文的文献

1
A Perspective on Therapeutic Targeting Against Ubiquitin Ligases to Stabilize Tumor Suppressor Proteins.靶向泛素连接酶以稳定肿瘤抑制蛋白的治疗前景
Cancers (Basel). 2025 Feb 13;17(4):626. doi: 10.3390/cancers17040626.
2
Genetic and clinical characteristics of genetic tumor syndromes in the central nervous system cancers: Implications for clinical practice.中枢神经系统癌症中遗传性肿瘤综合征的遗传和临床特征:对临床实践的意义。
iScience. 2024 Sep 30;27(11):111073. doi: 10.1016/j.isci.2024.111073. eCollection 2024 Nov 15.
3
Decoding the molecular symphony: interactions between the mA and p53 signaling pathways in cancer.

本文引用的文献

1
Genomic and Molecular Landscape of DNA Damage Repair Deficiency across The Cancer Genome Atlas.癌症基因组图谱中 DNA 损伤修复缺陷的基因组和分子特征。
Cell Rep. 2018 Apr 3;23(1):239-254.e6. doi: 10.1016/j.celrep.2018.03.076.
2
A pan-cancer genome-wide analysis reveals tumour dependencies by induction of nonsense-mediated decay.泛癌症全基因组分析通过诱导无义介导的衰变揭示肿瘤依赖性。
Nat Commun. 2017 Jun 26;8:15943. doi: 10.1038/ncomms15943.
3
A network-based drug repositioning infrastructure for precision cancer medicine through targeting significantly mutated genes in the human cancer genomes.
解码分子交响曲:癌症中mA与p53信号通路之间的相互作用
NAR Cancer. 2024 Sep 26;6(3):zcae037. doi: 10.1093/narcan/zcae037. eCollection 2024 Sep.
4
Identify Non-mutational p53 Functional Deficiency in Human Cancers.鉴定人类癌症中p53的非突变性功能缺陷。
Genomics Proteomics Bioinformatics. 2024 Dec 3;22(5). doi: 10.1093/gpbjnl/qzae064.
5
Therapeutic Strategies for RB1-Deficient Cancers: Intersecting Gene Regulation and Targeted Therapy.RB1基因缺陷型癌症的治疗策略:基因调控与靶向治疗的交叉点
Cancers (Basel). 2024 Apr 19;16(8):1558. doi: 10.3390/cancers16081558.
6
Ubiquitin-conjugating enzyme E2C (UBE2C) is a prognostic indicator for cholangiocarcinoma.泛素连接酶 E2C(UBE2C)是胆管癌的预后指标。
Eur J Med Res. 2023 Dec 15;28(1):593. doi: 10.1186/s40001-023-01575-9.
7
Detection of Biallelic Loss of DNA Repair Genes in Formalin-Fixed, Paraffin-Embedded Tumor Samples Using a Novel Tumor-Only Sequencing Panel.利用新型肿瘤特异性测序 panel 检测福尔马林固定石蜡包埋肿瘤样本中的双等位基因 DNA 修复基因缺失。
J Mol Diagn. 2023 May;25(5):295-310. doi: 10.1016/j.jmoldx.2023.02.004. Epub 2023 Mar 20.
8
Efficient Simultaneous Introduction of Premature Stop Codons in Three Tumor Suppressor Genes in PFFs via a Cytosine Base Editor.通过胞嘧啶碱基编辑器在 PFFs 中高效同时引入三个肿瘤抑制基因中的提前终止密码子。
Genes (Basel). 2022 May 7;13(5):835. doi: 10.3390/genes13050835.
9
Hereditary retinoblastoma iPSC model reveals aberrant spliceosome function driving bone malignancies.遗传性视网膜母细胞瘤 iPSC 模型揭示了导致骨恶性肿瘤的异常剪接体功能。
Proc Natl Acad Sci U S A. 2022 Apr 19;119(16):e2117857119. doi: 10.1073/pnas.2117857119. Epub 2022 Apr 11.
10
Glutaminase 2 functions as a tumor suppressor gene in gastric cancer.谷氨酰胺酶2在胃癌中作为一种肿瘤抑制基因发挥作用。
Transl Cancer Res. 2020 Aug;9(8):4906-4913. doi: 10.21037/tcr-20-2246.
一种基于网络的药物重新定位基础设施,用于精准癌症医学,通过靶向人类癌症基因组中显著突变的基因。
J Am Med Inform Assoc. 2016 Jul;23(4):681-91. doi: 10.1093/jamia/ocw007. Epub 2016 Mar 28.
4
Disordered methionine metabolism in MTAP/CDKN2A-deleted cancers leads to dependence on PRMT5.MTAP/CDKN2A 缺失型癌症中的蛋氨酸代谢紊乱导致对 PRMT5 的依赖性。
Science. 2016 Mar 11;351(6278):1208-13. doi: 10.1126/science.aad5944. Epub 2016 Feb 11.
5
TSGene 2.0: an updated literature-based knowledgebase for tumor suppressor genes.TSGene 2.0:一个基于文献更新的肿瘤抑制基因知识库。
Nucleic Acids Res. 2016 Jan 4;44(D1):D1023-31. doi: 10.1093/nar/gkv1268. Epub 2015 Nov 20.
6
Loss of heterozygosity: what is it good for?杂合性缺失:它有什么作用?
BMC Med Genomics. 2015 Aug 1;8:45. doi: 10.1186/s12920-015-0123-z.
7
Individualized iterative phenotyping for genome-wide analysis of loss-of-function mutations.用于功能丧失突变全基因组分析的个体化迭代表型分析
Am J Hum Genet. 2015 Jun 4;96(6):913-25. doi: 10.1016/j.ajhg.2015.04.013.
8
Suppression of SOX7 by DNA methylation and its tumor suppressor function in acute myeloid leukemia.DNA 甲基化抑制 SOX7 及其在急性髓系白血病中的肿瘤抑制功能。
Blood. 2015 Jun 18;125(25):3928-36. doi: 10.1182/blood-2014-06-580993. Epub 2015 May 4.
9
Comparison and integration of deleteriousness prediction methods for nonsynonymous SNVs in whole exome sequencing studies.全外显子组测序研究中非同义单核苷酸变异有害性预测方法的比较与整合
Hum Mol Genet. 2015 Apr 15;24(8):2125-37. doi: 10.1093/hmg/ddu733. Epub 2014 Dec 30.
10
TRIM35 Interacts with pyruvate kinase isoform M2 to suppress the Warburg effect and tumorigenicity in hepatocellular carcinoma.TRIM35 通过与丙酮酸激酶同工酶 M2 相互作用抑制肝癌的瓦博格效应和致瘤性。
Oncogene. 2015 Jul 23;34(30):3946-56. doi: 10.1038/onc.2014.325. Epub 2014 Sep 29.